The novel histone deacetylase inhibitor pracinostat suppresses the malignant phenotype in human glioma

Introduction: Glioma is the most common malignant brain tumor in adults. The effects of conventional treatment regimens are still limited to prolonging the survival of patients. Histone deacetylases (HDACs) are potential targets for tumor treatment. Pracinostat is a new type of HDAC inhibitor (HDACi) that has a significant antitumor effect on a variety of tumors. Thus, we aim to investigate the role of pracinostat in human glioma and explored its underlying mechanism.

Methods: Cell viability, proliferation and apoptosis of human glioma cell lines were measured by Cell Counting kit 8 and flow cytometry. Pathway verification and protein interaction were determined by quantitative real-time polymerase chain reaction, Western blotting and immunofluorescence staining. Transwell technology was used to assess the migration and invasion of cells. Clinical significance of TIMP3, MMP9 and MMP2 in glioma was analyzed through The Cancer Genome Atlas (TCGA) database and the Genotype-Tissue Expression (GTEx) database.

Results: Functionally, pracinostat not only inhibited proliferation and induced apoptosis but also inhibited migration and invasion in human glioma cell lines. Mechanistically, pracinostat increased the expression of TIMP3 and decreased the expression of MMP2, MMP9 and VEGF in human glioma cells in vitro and in vivo. In addition, pracinostat inhibited both the PI3K/Akt signaling pathway and the STAT3 pathway.

Conclusions: Our results strongly support the potential clinical use of pracinostat as a novel therapy for human glioma in the near future.

Comments：

Pracinostat is a new type of HDAC inhibitor that has a significant antitumor effect on human glioma, inhibiting proliferation, inducing apoptosis, inhibiting migration and invasion, and modulating the expression of TIMP3, MMP2, MMP9, and VEGF while inhibiting the PI3K/Akt and STAT3 pathways.

 

Related Products

Cat.No.	Product Name	Information
S1515	Pracinostat (SB939)	Pracinostat (SB939) is a potent pan-HDAC inhibitor with IC50 of 40-140 nM with exception for HDAC6. It has no activity against the class III isoenzyme SIRT I. Pracinostat (SB939) induces apoptosis in tumor cells. Phase 2.

Related Targets

HDAC Apoptosis related